Health Care & Life Sciences » Pharmaceuticals | TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
29.84 M
Public Float
22.05 M
TRACON Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.13
Market Cap
$18.54 M
Shares Outstanding
29.9 M
Public Float
20.61 M

Profile

Address
4350 La Jolla Village Drive
San Diego California 92122
United States
Employees -
Website http://www.traconpharma.com
Updated 07/08/2019
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company products include TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, TRC205 an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Financials

View All

Charles P. Theuer
President, CEO, CFO, Director & CAO
Theodore Wang
Independent Director